# DoW Toxic Exposures Clinical Trial Award (HT942526TERPCTA)

**Plain-English Eligibility Score:** 43/100

| Field | Value |
|---|---|
| Opportunity number | HT942526TERPCTA |
| Title | DoW Toxic Exposures Clinical Trial Award |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | posted |
| Posted / open date | 2026-05-21 |
| Close date | 2026-11-19 |
| Award ceiling | n/a |
| Award floor | n/a |
| Estimated total funding | $4,500,000 |
| Funding category | Science and Technology and other Research and Development |
| Eligible applicants | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
| CFDA / Assistance listing | 12.420 |
| Summary | Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations. Dist |
| Agency contact | help@eBRAP.org |

## Why this score
- Eligibility is unrestricted.
- Only 14 days until the deadline.

Source: Grants.gov (U.S. Department of Health and Human Services) (https://www.grants.gov/search-results-detail/362302). Last refreshed: 2026-11-04T18:11:59.874Z.
Data from Grants.gov. Always read the full notice of funding opportunity before applying. Informational only; not legal or grant-writing advice.